CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer

Esteva, Francisco; Wang, Jing; Lin, Feng; Mejia, Jaime; Yan, Kai; Altundag, Kadri; Valero, Vicente; Buzdar, Aman; Hortobagyi, Gabriel; Symmans, W.; Pusztai, Lajos

doi:10.1186/bcr1836

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer

Esteva F. J., Wang J., Lin F., Mejia J. A., Yan K., Altundag K., ...Daha Fazla

BREAST CANCER RESEARCH, cilt.9, sa.6, 2007 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 9 Sayı: 6
Basım Tarihi: 2007
Doi Numarası: 10.1186/bcr1836
Dergi Adı: BREAST CANCER RESEARCH
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Hacettepe Üniversitesi Adresli: Evet

Özet

Introduction We performed gene expression analysis to identify molecular predictors of resistance to preoperative concomitant trastuzumab and paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (T/FEC).